HALOZYME THERAPEUTICS, INC. Operating Leases, Future Minimum Payments, Due in Five Years
HALOZYME THERAPEUTICS, INC. (HALO) had Operating Leases, Future Minimum Payments, Due in Five Years of $112.00 thousand as of 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears · last filed 2019-02-21
- 2018-12-31: Operating Leases, Future Minimum Payments, Due in Five Years $112.00K.
- 2017-12-31: Operating Leases, Future Minimum Payments, Due in Five Years $2.51M.
- 2016-12-31: Operating Leases, Future Minimum Payments, Due in Five Years $36.00K.
- 2015-12-31: Operating Leases, Future Minimum Payments, Due in Five Years $426.00K.
| Period end | Operating Leases, Future Minimum Payments, Due in Five Years |
|---|---|
| 2018-12-31 | $112.00K 10-K · filed 2019-02-21 |
| 2017-12-31 | $2.51M 10-K · filed 2018-02-20 |
| 2016-12-31 | $36.00K 10-K · filed 2017-02-28 |
| 2015-12-31 | $426.00K 10-K · filed 2016-02-29 |
| 2013-12-31 | $80.00K 10-K · filed 2014-02-28 |
| 2012-12-31 | $2.13M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |